Search Within

Hematologic Malignancies, Division of

Formats
  1. Meeting Abstract (6372)
  2. Journal Article (5781)
  3. Review (421)
  4. Editorial (196)
  5. Book Section (188)
  6. Research Letter (179)
  7. Guidelines (88)
  8. Conference Paper (65)
  9. Correspondence (62)
  10. Miscellaneous (18)
  11. Book Whole (9)
Groups
  1. Department of Medicine (13278)
  2. Center for Hematologic Malignancies (10612)
  3. GSK Faculty (4482)
  4. Adult Leukemia (3673)
  5. Bone Marrow Transplant (2848)
  6. Lymphoma (2705)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (943)
  3. Ross Levine (787)
  4. Andrew Zelenetz (784)
  5. Steven Horwitz (669)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (340)
  2. 2024 (823)
  3. 2023 (1038)
  4. 2022 (964)
  5. 2021 (875)
  6. 2020 (936)

More Years

Publications
  1. Blood (3529)
  2. Journal of Clinical Oncology (1233)
  3. Biology of Blood and Marrow Transplantation (596)
  4. Clinical Lymphoma, Myeloma and Leukemia (330)
  5. Haematologica (292)
  6. Bone Marrow Transplantation (239)

More Publications

Publishers
  1. American Society of Hematology (3806)
  2. Elsevier Inc. (1530)
  3. American Society of Clinical Oncology (1288)
  4. Nature Publishing Group (1009)
  5. American Association for Cancer Research (641)
  6. Wiley Blackwell (433)

More Publishers

Results (13379)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Identifying molecular drivers of olaparib resistance through genome-wide sgRNA screening in prostate organoids
    Meeting Abstract

    Pappas, K. J.; Karthaus, W.; Laclair, J.; Russo, M.; Sawyers, C.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • MSK-ACCESS Heme: A cell-free DNA next-generation sequencing assay to identify somatic alterations in patients with lymphoma
    Meeting Abstract

    DiNapoli, S. E.; Spence, C.; Gedvilaite, E.; Bowman, A.; Diosdado, M.; Razumova, A.; Tsui, D.; Salles, G. A.; Batlevi, C.; von Keudell, G.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Combination of cyclophosphamide with immune checkpoint blockade inhibition elicits potent tumor control in a preclinical melanoma model
    Meeting Abstract

    George, M. M.; Warner, A. B.; Hamadene, L.; Hirschhorn, D.; Houghton, A. N.; Wolchok, J. D.; Merghoub, T.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Acute kidney injury induced by allogeneic hematopoietic stem cell transplantation: disease understanding and treatment with nanotechnology-based therapeutics
    Meeting Abstract

    Panagiotakopoulou, M.; Grabarnik, E.; Jaimes, E. A.; van den Brink, M. R.; Heller, D. A.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Activating canonical p53 functions in tumor-associated macrophages improves immune checkpoint blockade efficacy
    Meeting Abstract

    Ghosh, A.; Michel, J.; Venkatesh, D.; Mezzadra, R.; Dong, L.; Samaan, F.; Gomez, R.; Suek, N.; Holland, A.; Ho, Y. J.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Pharmacologically induced polyploidy triggers BCL2 dependence in lymphomas
    Meeting Abstract

    Portelinha, A.; da Silva Ferreira, M.; Erazo, T.; Asgari, Z.; de Stanchina, E.; Younes, A.; Wendel, H. G.
    Cancer Research (2022)

    Fulltext@MSK | Save
  • OncoKB, MSK's precision oncology knowledge base
    Meeting Abstract

    Suehnholz, S. P.; Nissan, M.; Zhang, H.; Kundra, R.; Lu, C.; Dhaneshwar, A.; Fernandez, N.; Carrero, S.; Arcila, M. E.; Ladanyi, M.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • Ttafasitamab plus lenalidomide (TAFA+LEN) versus pola-BR, r2, and CAR-T in non-transplant eligible (NTE) relapsed/refractory (r/r) DLBCL: A post hoc analysis of the RE-MIND2 study comparing multiple cohort-balancing approaches
    Meeting Abstract

    Córdoba, R.; Zinzani, P. L.; Joffe, E.; Yoon, D. H.; Peters, A.; Waltl, E. E.; Alvero, C.; Sabatelli, L.; Salles, G.; Nowakowski, G. S.
    Value in Health (2022)

    Fulltext@MSK | Save
  • Health care resource utilization with asciminib and bosutinib among adults with chronic myeloid leukemia in chronic phase previously treated with ≥2 tyrosine kinase inhibitors: Week 48 and week 96 results from ASCEMBL trial
    Meeting Abstract

    Cortes, J. E.; Sasaki, K.; Réa, D.; Mauro, M. J.; Tran, D.; Wang, P.; Jadhav, K.; Di Caprio, L.; Yocolly, A.
    Value in Health (2022)

    Fulltext@MSK | Save
  • AXL tyrosine kinase mediates escape from type II JAK2 inhibition in myeloproliferative neoplasms
    Meeting Abstract

    Codilupi, T.; Szybinski, J.; Brkic, S.; Stivala, S.; Yang, J. L.; Ghosh, N.; Passweg, J. R.; Angelillo-Scherrer, A.; Dirnhofer, S.; Levine, R. L.; more...
    Swiss Medical Weekly (2022)

    Fulltext@MSK | Save